- Report
- March 2024
- 181 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Clinical Trials
- April 2024
- 70 Pages
Global
From €1445EUR$1,500USD£1,242GBP
- Report
- June 2023
- 168 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Clinical Trials
- April 2024
- 110 Pages
Global
From €1445EUR$1,500USD£1,242GBP
- Report
- January 2022
- 60 Pages
Global
From €3804EUR$3,950USD£3,271GBP
- Report
- January 2022
- 200 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- January 2022
- 60 Pages
Global
From €3804EUR$3,950USD£3,271GBP
- Report
- January 2022
- 200 Pages +
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- May 2018
- 88 Pages
Global
From €2793EUR$2,900USD£2,402GBP
- Drug Pipelines
- July 2022
- 71 Pages
Global
From €6736EUR$6,995USD£5,793GBP
- Drug Pipelines
- October 2020
- 110 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Report
- February 2024
- 89 Pages
Global
From €3500EUR$3,893USD£3,115GBP
- Report
- August 2022
- 112 Pages
Global
From €1926EUR$2,000USD£1,656GBP
Bronchiectasis is a chronic lung disease that causes irreversible damage to the airways. It is characterized by abnormal and irreversible widening of the bronchi, leading to recurrent infections and difficulty breathing. Treatment for bronchiectasis includes antibiotics, bronchodilators, and mucolytics. Inhaled corticosteroids may also be used to reduce inflammation.
The bronchiectasis drug market is a subset of the larger respiratory drug market. It is composed of drugs used to treat bronchiectasis, including antibiotics, bronchodilators, mucolytics, and inhaled corticosteroids. These drugs are used to reduce inflammation, reduce mucus production, and improve airway clearance.
Some companies in the bronchiectasis drug market include GlaxoSmithKline, AstraZeneca, Merck, Novartis, and Boehringer Ingelheim. Show Less Read more
